Emkay
Refer to important disclosures at the end of this report Revenue guidance and Halol restart a positive; events factored in earnings Q4FY18 results had a number of one-offs, including higher operating income (milestone from Almirall), significantly higher non-operating income and tax write-backs. Adjusting for these, operating revenue and EBITDA largely stood in line with expectations. FY19 revenue guidance at low teens growth, significant incremental investments in R&D; & building of front-end marketing for the Branded business. The US Branded business...
Number of FII/FPI investors decreased from 1351 to 1326 in Jun 2025 qtr
More from Sun Pharmaceutical Industries Ltd.
Recommended